Pharmaceutical

EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.

Sep 14, 2024 - 04:00
EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity
The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.
Read the original article

Tags:

Previous Article

Moderna cuts five programmes to save $1.1bn in R&D costs

Next Article

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Key House Democrat demands NIH answer for pace of long Covid research

Key House Democrat demands NIH answer for pace of long ...

May 11, 2023

STAT+: FTC plans to reverse years of policy statements supporting pharmacy benefit managers

STAT+: FTC plans to reverse years of policy statements ...

Jul 20, 2023

STAT+: Humana projects a tough road for Medicare Advantage, sinking its stock

STAT+: Humana projects a tough road for Medicare Advant...

Jan 26, 2024